文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Value of serum pepsinogen ratio screening for early gastric cancer and precancerous lesions in Youcheng area.

作者信息

Han Xue, Yu Wei

机构信息

Department of General Practice, Shengli Oilfield Central Hospital, Dongying 257000, Shandong Province, China.

Health Management Center, Shengli Oilfield Central Hospital, Dongying 257000, Shandong Province, China.

出版信息

World J Gastrointest Surg. 2024 Dec 27;16(12):3729-3736. doi: 10.4240/wjgs.v16.i12.3729.


DOI:10.4240/wjgs.v16.i12.3729
PMID:39734444
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11650226/
Abstract

BACKGROUND: The 5-year survival rate of patients with advanced gastric cancer remains extremely low (< 15%), whereas the 5-year survival rate of patients with early gastric cancer (EGC) is > 90%. Consequently, strengthening the screening of patients with EGC and precancerous lesions (PCLs) is essential. AIM: To identify the value of serum pepsinogen ratio (PGR) screening for EGC and PCLs in the Shengli Oilfield Central Hospital. METHODS: We first selected 385 patients with gastric lesions in the Youcheng area, determining benign lesions, PCLs, and EGC in 135, 123, and 127 cases, respectively, based on endoscopy and case diagnosis. The positive rates of pepsinogen I, pepsinogen II and () in the three groups were detected, and the PGR was calculated. Subsequently, we plotted receiver operating characteristic curves to analyze the screening value of PGR and -positive rates for PCLs and EGC. RESULTS: PGR expression demonstrated a decreasing trend in patients with benign lesions, PCLs, and EGC successively according to the detection results, whereas the -positive rate was notably increased in patients with PCLs and EGC compared to those with benign lesions. The area under the curves (AUCs) of PGR, , and their combination in differentiating patients with benign lesions from those with PCLs were 0.611, 0.582, and 0.689, respectively; PGR, , and their combination had an AUC of 0.618, 0.502, and 0.618 in distinguishing PCL patients from EGC patients, respectively; the AUCs of PGR, , and their combination in discriminating patients with benign lesions from those with EGC were 0.708, 0.581, and 0.750, respectively. CONCLUSION: PGR has great screening potential for patients with EGC and PCLs in the Youcheng area, and the screening efficiency is further improved by combining the -positive rate.

摘要

相似文献

[1]
Value of serum pepsinogen ratio screening for early gastric cancer and precancerous lesions in Youcheng area.

World J Gastrointest Surg. 2024-12-27

[2]
[Comparison of different serological methods in screening early gastric cancer].

Zhonghua Nei Ke Za Zhi. 2019-4-1

[3]
Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies.

J Dig Dis. 2007-2

[4]
The application of new gastric cancer screening score system for gastric cancer screening and risk assessment of gastric precancerous lesions in China.

Scand J Gastroenterol. 2023-1

[5]
[Diagnostic Value of Serum Pepsinogen Ⅰ/Pepsinogen Ⅱ Combined with Tumor Markers for -Positive Early-Stage Gastric Cancer].

Sichuan Da Xue Xue Bao Yi Xue Ban. 2023-1

[6]
Helicobacter pylori Infection and Serum Pepsinogen Level With the Risk of Gastric Precancerous Conditions: A Cross-sectional Study of High-risk Gastric Cancer Population in China.

J Clin Gastroenterol. 2021-10-1

[7]
Early gastric cancer and Helicobacter pylori: 34 years of experience at Charity Hospital in New Orleans.

Am Surg. 1998-6

[8]
[A comparative study of new gastric cancer screening scoring system and new ABC method for screening gastric cancer and precancerous lesions].

Zhonghua Nei Ke Za Zhi. 2021-3-1

[9]
Receiver operating characteristic analysis of prediction for gastric cancer development using serum pepsinogen and Helicobacter pylori antibody tests.

BMC Cancer. 2017-3-9

[10]
Proteomic and serological markers for diagnosing cardia gastric cancer and precursor lesions in a Chinese population.

Sci Rep. 2024-10-25

本文引用的文献

[1]
Global progress and future prospects of early gastric cancer screening.

J Cancer. 2024-4-8

[2]
Chinese national clinical practice guidelines on the prevention, diagnosis, and treatment of early gastric cancer.

Chin Med J (Engl). 2024-4-20

[3]
Clinical value of serum pepsinogen in the diagnosis and treatment of gastric diseases.

World J Gastrointest Oncol. 2023-7-15

[4]
Endoscopic Resection of Early Gastric Cancer and Pre-Malignant Gastric Lesions.

Cancers (Basel). 2023-6-7

[5]
Comparison of Gastric Cancer Risk Classifications Using Conventional and New Pepsinogen Criteria.

Gastroenterol Res Pract. 2023-5-30

[6]
The application of new gastric cancer screening score system for gastric cancer screening and risk assessment of gastric precancerous lesions in China.

Scand J Gastroenterol. 2023-1

[7]
How Does Infection Cause Gastric Mucosal Atrophy.

Infect Drug Resist. 2022-7-7

[8]
Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data.

Cancer Epidemiol Biomarkers Prev. 2022-7-1

[9]
Endoscopic Classifications of Early Gastric Cancer: A Literature Review.

Cancers (Basel). 2021-12-26

[10]
Pepsinogen II in gastritis and Helicobacter pylori infection.

Helicobacter. 2022-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索